What is the appropriate Paxlovid (nirmatrelvir/ritonavir) dosing regimen for COVID-19?

Paxlovid Dosing for COVID-19

The standard dose of Paxlovid is nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one 100 mg tablet) taken together orally twice daily for 5 days, initiated as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset. 1, 2

Standard Dosing Regimen

• Dose: Nirmatrelvir 300 mg + ritonavir 100 mg (3 tablets total)
• Frequency: Twice daily (approximately every 12 hours)
• Duration: 5 days
• Timing: Start within 5 days of symptom onset
• Administration: Can be taken with or without food 3, 1

Dose Adjustments for Renal Impairment

Moderate Renal Impairment (eGFR 30-59 mL/min):

• Nirmatrelvir 150 mg (one 150 mg tablet) + ritonavir 100 mg (one 100 mg tablet)
• Twice daily for 5 days 3, 1

Severe Renal Impairment (eGFR <30 mL/min), including hemodialysis:

The FDA label has been updated with new dosing recommendations 1:

• Day 1: Nirmatrelvir 300 mg (two 150 mg tablets) + ritonavir 100 mg once
• Days 2-5: Nirmatrelvir 150 mg (one 150 mg tablet) + ritonavir 100 mg once daily
• For hemodialysis patients: Administer dose after dialysis on dialysis days 1

This represents a significant change from previous recommendations that contraindicated use in severe renal impairment, now supported by the EPIC-SRI study demonstrating safety and adequate drug exposure with this regimen 4.

Hepatic Impairment

• Mild to moderate hepatic impairment: No dose adjustment needed
• Severe hepatic impairment (Child-Pugh Class C): Not recommended 1, 2

Critical Clinical Considerations

Who Should Receive Paxlovid

Strong recommendation for patients with non-severe COVID-19 at high risk of hospitalization 3. High certainty evidence shows important reduction in hospitalization and moderate certainty for survival benefit.

Conditional recommendation for patients at moderate risk of hospitalization 3. Benefits are smaller but still potentially important.

Conditional recommendation against use in low-risk patients 3. Benefits are trivial in this population.

Drug Interactions - Critical Safety Issue

This is the most important clinical pitfall. Ritonavir is a potent CYP3A4 inhibitor that causes extensive drug-drug interactions 3, 1. Before prescribing:

1. Review ALL patient medications for CYP3A4 interactions
2. Use the Liverpool COVID-19 drug interaction tool 3
3. Determine if concomitant medications need dose adjustment, temporary discontinuation, or additional monitoring
4. Contraindicated with drugs highly dependent on CYP3A4 where elevated levels cause serious/life-threatening reactions 1, 2
5. Contraindicated with potent CYP3A4 inducers that would reduce nirmatrelvir/ritonavir levels 1, 2

Special Populations

Pregnancy: Represents an option for pregnant patients to reduce disease progression, though uncertainty exists regarding potential adverse reactions. No serious reactions reported in WHO Vigibase to date 3

HIV-1 infection: Risk of developing HIV protease inhibitor resistance in uncontrolled or undiagnosed HIV-1 infection 1, 2

Common Adverse Effects

Most frequent adverse reactions (>1%):

• Dysgeusia (altered taste)
• Diarrhea 1, 2

Serious but rare: Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity 1, 2

Comparative Effectiveness

Paxlovid is the superior choice over molnupiravir (greater hospitalization reduction, safety concerns with molnupiravir) and remdesivir (practical issues with IV administration), provided drug interactions can be managed 3. Do not combine antiviral therapies - no evidence supports this approach 3.